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Background
Low concentrations of histone deacetylase (HDAC) inhi-
bitors exhibit anti-inflammatory properties including
animal models of arthritis [1]. Here we review possible
mechanisms of action in arthritis and present results of
HDAC inhibitor givinostat influence on cytokine net-
work in patients with systemic JIA (SOJIA).
Methods
Givinostat was orally administered for up to 12 weeks at
a dose of 1.5 mg/kg/day in 17 SOJIA patients [2] with
average disease duration of 59.53±49.16 months and
duration of active disease of 14.19±24.41 months. Clini-
cal assessment of disease activity was performed using
ACR Pedi 30, 50 or 70 and a systemic feature score.
Cytokines were measured in hole blood lysates using
R&D Systems (Mosaic
TM ELISA) human cytokine panel.
Results
Givinostat was safe and well tolerated with adverse
events being mild or moderate, of short duration and
self-limiting. Out of 17 patients who entered the study,
ten completed the 12 weeks of treatment (58.8%). At
week 4, the mean systemic feature score significantly
decreased from 5.24 ± 0.37 to 2.59 ± 0.33 and the ACR
Pedi 30, 50 or 70 improvement was 77.8%, 55.6% and
22.2%. At week 12, the ACR scores increased further to
77.8%, 77.8% and 66.7%, respectively. The most consis-
tent finding was the reduction in the number of active
joints and/or joints with limited range of motion. At
week 4, in patients with baseline WBC of 12,000 or
greater (N=11), there was a significant decrease (p<0.01)
in the total WBC and absolute numbers of neutrophils
(-30.6 and – 29.8 Δ% from baseline, respectively). Cyto-
kines in whole blood lysates were elevated at baseline
but after 2 and 4 weeks of givinostat, CD40L (p<0.05),
IL 1a (p<0.001) and IFNg normalised.
Conclusion
HDAC inhibition by givinostat was safe and resulted in
significant improvement of arthritis in SOJIA, as well as
normalized cytokine and hematological parameters. We
hypotheses possible use instead methotrexate to treat
JIA after further investigations.
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